Cassava Sciences, Inc. (SAVA)
NASDAQ: SAVA · IEX Real-Time Price · USD
22.03
+0.29 (1.36%)
Apr 26, 2024, 12:01 PM EDT - Market open
Company Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.
Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Cassava Sciences, Inc.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Remi Barbier |
Contact Details
Address: 6801 N Capital Of Texas Highway, Building 1; Suite 300 Austin, Texas 78731 United States | |
| Phone | 512-501-2444 |
| Website | cassavasciences.com |
Stock Details
| Ticker Symbol | SAVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001069530 |
| CUSIP Number | 14817C107 |
| ISIN Number | US14817C1071 |
| Employer ID | 91-1911336 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Remi Barbier | Founder, Chairman, President and Chief Executive Officer |
| Eric J. Schoen | Chief Financial Officer |
| R. Christopher Cook | Senior Vice President, Company Secretary and General Counsel |
| Dr. James W. Kupiec M.D. | Chief Medical Officer |
| Dr. George Thornton Ph.D. | Senior Vice President of Technology |
| Michael Zamloot | Senior Vice President of Technical Operations |
| Dr. Michael Marsman Pharm.D. | Senior Vice President of Regulatory Affairs |
| Dr. Lindsay H. Burns Ph.D. | Senior Vice President of Neuroscience |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | 8-K | Current Report |
| Mar 26, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 22, 2024 | ARS | Filing |
| Feb 28, 2024 | 10-K | Annual Report |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 7, 2024 | 8-K | Current Report |
| Feb 1, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 26, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 3, 2024 | CERT | Certification by an exchange approving securities for listing |